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Abstract 
Neurotrauma represents a major public health problem and is one of the leading causes of death and disability 
worldwide. Despite its high prevalence, there are major gaps in our understanding of the underlying patho-
physiology leading to the substantial morbidity and mortality associated with this problem. Here, ten studies 
published in 2019 are reviewed that addressed issues related to the acute and long-term effects of neurotrau-
ma. These studies can be broken down into three separate categories, namely, the importance of neurotrau-
ma-based damage to the cerebrovascular unit, white matter damage following neurotrauma, and research 
related to the long-term neurodegenerative consequences of repeated head trauma, especially chronic trau-
matic encephalopathy. The advances highlighted here indicate that progress has been made. However, major 
gaps in knowledge remain which will require additional neuropathologic studies of clinical specimens, as well as 
the development and investigation of a wide range of relevant pre-clinical models. Further efforts in this field 
are clearly needed if there are to emerge better clinical outcomes for the numerous patients that suffer neuro-
trauma each year as well as those currently suffering from its long-term effects. 
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Abbreviations 
CHIMERA - Closed-Head Impact Model of Engi-
neered Rotational Acceleration, cryo-EM - cryo electron 
microscopy, CRASH - Clinical Randomisation of an Anti-
fibrinolytic in Significant Haemorrhage, CT - computer-
ized tomography, CTE - chronic traumatic encephalopa-
thy, GCS - Glasgow Coma Scale, GFAP - glial fibrillary 
acidic protein, MRI - magnetic resonance imaging, mTBI 
- mild traumatic brain injury, NFL - National Football 
League, PET - positron emission tomography, TBI - trau-
matic brain injury, WT - wild type. 
Introduction 
According to PubMed, in 2019 there appeared 
2,508 publications which included traumatic brain injury 
(TBI) as a keyword. This compares to 886 papers with TBI 
as a keyword published in 2009. Each year, over the past 
decade, there has been a steady increase in publications, 
Review 
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addressing this topic (see figure 1). This almost three-
fold increase in published reports over the past decade 
reflects, I believe, increasing awareness of the im-
portance of the health issues related to neurotrauma, 
opportunities for neurotrauma research, as well as in-
creased funding for research on the topic. However, as 
will be pointed out, despite this increased research at-
tention, there is much more to be done. 
 
 
Figure 1: No. of TBI Papers Published 
(source: www.ncbi.nlm.nih.gov/pubmed) 
 
According to the Centers for Disease Control and 
Prevention, in the United States, in 2014 there were 2.87 
million TBI-related emergency room admissions, 288,000 
hospital admissions and 56,800 deaths (155 per day) 
(see www.cdc.gov/traumaticbraininjury). That number 
of annual deaths is greater than occurs each year related 
to other, more widely recognized, health issues such as 
breast cancer (42,170 deaths, data from the American 
Cancer Society), colon and rectal cancer (53,200 deaths, 
data from the American Cancer Society), pancreatic 
cancer (47,050 deaths, data from the American Cancer 
Society) and influenza (51,376 deaths, data from 2014-
15 from the CDC) (see www.cancer.org and 
www.cdc.gov/flu as sources of data on death rates). 
A further reason for increasing attention to neuro-
trauma has been concerns about the long-term effects 
of TBI on the brain and the possible link to the subse-
quent development of neurodegenerative disorders. 
There has also been increasing interest among the US 
Department of Defense and Veterans Administration in 
both the acute and the long-term effects of impact and 
blast TBI among the more than 2 million military service 
members who have been deployed to the Middle East to 
fight the war against terrorism. Finally, there has been 
particular concern about the long-term effects of partic-
ipation in contact sports, such as American football, with 
the occurrence of repeated concussive and subconcus-
sive impact TBIs and a risk of developing chronic trau-
matic encephalopathy (CTE). All of this has combined to 
promote increasing attention to neurotrauma research. 
Obviously I was not able to review all 2,508 papers 
appearing in the past year in making my selections of the 
most important contributions to this field. I readily ad-
mit that there is a degree of personal bias to those I 
have chosen, however, the following is a list of what I 
consider to be the most influential papers to have ap-
peared in the past year, plus comments on how I believe 
they have influenced both clinical and pre-clinical con-
cepts. 
Role of the Vasculature in TBI Patho-
physiology 
In 2019, there have been several reports that high-
lighted the importance of the cerebrovascular unit in the 
pathophysiology of TBI. In 2019, this was emphasized by 
the positive results of a very large clinical trial (CRASH 
2019), the use of magnetic resonance imaging (MRI) and 
subsequent neuropathology correlation in TBI patients 
(Griffin, Turtzo et al. 2019) and a pre-clinical model of 
sub-concussive blast exposure in the rat (Gama Sosa, De 
Gasperi et al. 2019). 
Over the past several years, unfortunately, there 
have been a large number of failed clinical trials seeking 
to improve outcomes of acute victims of TBI. However, 
in 2019, a randomized placebo-controlled clinical trial on 
the effects of treatment by tranexamic acid on death 
and disability in patients with acute TBI (CRASH 2019) 
was successful. The rationale for this approach is that 
tranexamic acid reduces bleeding by inhibiting the en-
zymatic breakdown of fibrin blood clots. Fibrinolysis, 
with increased concentrations of fibrinogen degradation 
products, is commonly seen in the brains of acute TBI 
patients and predicts the development of further intra-
cranial hemorrhagic expansion (Zhang, He et al. 2018). 
The report involved an extremely large trial, consisting 
of a total of 12,737 hospitalized patients with acute TBI. 
Enrollment criteria included adults with TBI who were 
within 3 hours of injury, had a Glasgow Coma Scale (GCS) 
of 12 or lower or showed evidence of intracranial bleed-
ing on CT examination. The study clearly demonstrated 
that administration of tranexamic acid within 3 hours of 
head injury significantly reduced the risk of death. The 
authors stressed that early treatment was essential to 
elicit this effect and that patients with a GCS score of 3 
or less or who had non-reactive pupils at baseline failed 
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to show a reduction in death-rate. In the tranexamic 
acid-treated group, excluding patients with a GCS of 3 or 
with bilateral unreactive pupils at baseline, the risk of 
head-injury-related death was 12.5% versus 14.9% in the 
placebo group (485 vs 525 events; RR 0·89 [95% CI 0·80–
1·00]). In addition, their study demonstrated that 
tranexamic acid administration in the TBI patients had a 
very good safety record. The risks of serious vascular 
occlusive events (deep vein thrombosis, pulmonary 
embolism, stroke or myocardial infarction) or of seizures 
were not increased in the tranexamic treated patients 
when compared to the placebo group. 
Importantly, tranexamic acid is a widely available 
drug which is quite inexpensive. Indeed, the total cost of 
this medication, as given in the trial, was less than 
$10/patient! TBI is not just a problem in rich industrial-
ized countries, but is seen worldwide, especially in de-
veloping countries. TBI is a leading cause of death and 
disability worldwide, with an estimated 10,000,000 cas-
es being hospitalized or dying each year (Roberts, Belli et 
al. 2018). The low cost and demonstrated safety of this 
treatment makes it ideal for use throughout the world 
and, according to the authors, promises a dramatic im-
pact on the survival of large numbers of patients. This 
important paper reports what I believe is the first clinical 
drug trial to ever show significantly reduced mortality 
from TBI. It is promising for changing clinical practice 
and saving numerous lives, worldwide. 
For neuropathologists, this paper emphasizes the 
importance of bleeding and vascular ischemic lesions as 
important factors leading to fatal outcomes following 
head trauma. These aspects have been poorly docu-
mented and understood in the neuropathology litera-
ture and will require further investigation, both in a 
clinical setting and in pre-clinical models. 
An example of this approach is my next chosen 
publication which involves MRI and correlative neuropa-
thology in the evaluation of acute TBI patients (Griffin, 
Turtzo et al. 2019). Full disclosure requires that I identify 
myself as a participant in, and an author of this study 
which reports on the identification and characterization 
of microbleeds in the work-up of acute patients with TBI 
(Griffin, Turtzo et al. 2019). Nevertheless, the results 
reported are sufficiently important to include it on my 
list of important contributions to the field of neurotrau-
ma. 
Within the initial clinical workup of patients com-
ing into an emergency department following TBI is the 
use of CT examination looking for evidence of major 
sites of intracranial bleeding that might require surgical 
intervention. Some research groups have now begun to 
employ MRI imaging as a means of providing the more 
detailed morphologic spatial resolution inherent to this 
technology to the information available for acute TBI 
clinical management. In doing so, it has been noted that 
the brains of many TBI patients being evaluated in this 
way show the presence of multiple small, often punctate 
or linear hypointensities on T2-weighted imaging 
(Huang, Kuo et al. 2015, Chiara Ricciardi, Bokkers et al. 
2017). MRI lacks a cellular level of resolution leading to 
conjecture as to what the underlying pathology of these 
lesions might represent. Some have interpreted them to 
be traumatic microbleeds, while others have suggested 
them to represent the sites of hemorrhagic axonal inju-
ries. Importantly, whether such MRI findings may be 
used as a biomarker for predicting successful, partial, or 
poor recovery remains an unanswered question. 
The data in this study (Griffin, Turtzo et al. 2019) is 
from a large number of civilian TBI victims who were 
clinically evaluated in several urban trauma centers in 
the Washington, DC area. Eligible patients were entered 
into an MRI screening protocol along with further longi-
tudinal clinical follow-up. A total of 439 patients met 
inclusion criteria for the initial neuroradiologic analysis. 
Most of those enrolled were determined to have mTBI 
(83%), with a mean GCS at the time of initial evaluation 
of 15. Importantly, approximately one-third of these 
mild patients showed evidence of punctate and/or linear 
microbleeds on initial MRI exam, indicating that such 
lesions are not uncommon following mild and mostly 
asymptomatic head trauma. The presence of traumatic 
microbleeds was shown to be an independent predictor 
of subsequent disability in the cohort (P <0.05; odds 
ratio = 2.5). 
One of the patients who had received MRI within 
48 hours of injury and showed the presence of multiple 
punctate and linear intraparenchymal hemorrhages, 
died 7 months following the accident and was subjected 
to post-mortem examination with brain donation for use 
in research. Using the clinical MRI exams, supplemented 
by ex vivo imaging of the formalin fixed brain specimen, 
a correlational neuroimaging/neuropathology investiga-
tion was performed on the specimen in an attempt to 
identify the histopathologic nature of the punc-
tate/linear hemorrhages that had been identified. Using 
co-registration of the clinical and ex vivo MRI images 
with histopathologic stained sections, the post-traumatic 
microhemorrhages showed the presence of iron-laden 
macrophages, predominantly within perivascular spaces. 
In these colocalized histopathologic slides, evidence of 
axonal injury was not observed in conjunction with the 
microhemorrhages. This study highlights the importance 
of damage to the cerebral vasculature as a consequence 
of mTBI and its effect on clinical outcome. This result, 
combined with the findings of the previously discussed 
paper on the effectiveness of tranexamic acid, under-
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scores the importance of studying the effects of TBI on 
the integrity of the cerebrovasculature unit. We are far 
from knowing how best to use such MRI findings for a 
more rational therapeutic approach to patients. Howev-
er, additional correlational neuroimaging / neuropathol-
ogy studies of this type will clearly lead to important 
information that will, in the future, refine clinical diag-
nostic and treatment guidelines. 
In a further investigation of the role of the cere-
brovascular unit in the pathophysiology of TBI, Gama-
Sosa and colleagues reported findings in a pre-clinical rat 
model of repetitive mild blast TBI (Gama Sosa, De 
Gasperi et al. 2019). Using a blast tube facility, the dose 
of blast exposure to the rats was mild and determined to 
represent 74.5 kPa (equivalent to 10.8 psi) and animals 
were exposed to one blast per day, over three consecu-
tive days. Exposed rats were sacrificed at 6 weeks, 8 
months and 10 months following blast exposure. This 
model was considered to be a low level of blast expo-
sure, comparable to those endured by military Service 
Members in training activities and combat exercises 
(thus emphasizing the clinical relevance of this model), 
and exposed animals failed to show evidence of general-
ized neuronal pathology at either the light or electron 
microscopic level. However, upon detailed examination 
of the neurovascular unit, significant pathology was 
identified. Using purified vascular fractions, decreased 
levels of vascular-associated glial fibrillary acidic protein 
(GFAP) and that of several neuronal intermediate fila-
ment proteins (α-internexin and low, middle and high 
neurofilament proteins) were identified 6 weeks follow-
ing the blast exposure. Electron microscopy showed 
evidence of damage to astrocytic end-feet associated 
with blood vessels. At 8 months following blast expo-
sure, there was evidence of alterations of the vascular 
smooth muscle layer. These findings indicate that de-
spite the low dose of blast exposure, significant chronic 
vascular damage had been induced. These intriguing 
findings need to be further investigated and serve to add 
additional support to the importance of the above dis-
cussed papers. 
White Matter Involvement in TBI 
A consistent clinical finding in patients with TBI is 
slowing of information processing. Damage to neuronal 
circuitry, with disruption of long axons, is thought to play 
a major role in this phenomenon. In an attempt to mod-
el this aspect of TBI, a group experimentally studied 
aspects of TBI damage using a direct impact concussion 
model in mice (Marion, Radomski et al. 2018) that has 
previously been shown to induce traumatic axonal injury 
to the corpus callosum (Mierzwa, Marion et al. 2015). 
Animals were studied neurophysiologically and morpho-
logically. Following impact, compound action potential 
velocities along myelinated axons were slowed within 3 
days of injury with partial recovery of function by 2 
weeks. This suggested to the authors that partial demye-
lination, followed by remyelination was responsible for 
the changed action potential velocities. Using electron 
microscopy, dispersed demyelinated axons and disor-
ganized myelin attachments to axons at paranodes were 
noted within the corpus callosum of the injured mice. 
Animals examined after longer periods following TBI 
exhibited an overall loss of axons at 6 weeks post-injury 
and observable corpus callosum thinning was seen by 8 
weeks. 
White matter damage is a consistent finding in the 
brains of patients who survive TBI and have significant 
cognitive issues and conspicuous thinning of the corpus 
callosum is often noted in such patients (Johnson, Stew-
art et al. 2013). This paper provides a useful experi-
mental model for this phenomenon and is promising for 
a better understanding of the pathophysiology of such 
white matter damage and a substrate to explore treat-
ment options for patients with this important aspect of 
head trauma’s clinical effects. 
The year 2019 has, among other things, witnessed 
increasing attention to the MeToo movement, recogniz-
ing the high prevalence and importance of sexual har-
assment and violence against women. I was intrigued to 
find a publication which identified the importance of 
intimate partner violence as a substrate for TBI, as evi-
denced by its effects on the integrity of white matter 
(Valera, Cao et al. 2019). The authors point out that it is 
estimated that in the United States, about 42,000,000 
women over age 15 have experienced physical or sexual 
abuse and that 75% of women with a history of intimate-
partner violence have sustained at least one partner-
related TBI, while 50% have sustained repeated TBIs. 
Despite this staggering number of victims, there 
has been almost no study of the long-term functional 
and structural consequences of such violence. The Val-
era, et al preliminary study attempted to address this 
gap in knowledge by recruiting 20 women who had sus-
tained such intimate partner assaults, based on a de-
tailed semi-structured interview. Participants underwent 
detailed study, including 3T MRI neuroimaging. The 
neuroimaging aspects of the study revealed evidence of 
abnormalities in fractional anisotropy in the posterior 
and superior corona radiata as well as the posterior 
thalamic radiation. However, this was a preliminary 
study with limited power and lacked a control popula-
tion for comparison. Nevertheless, this paper identified 
a potentially very large group of women who are at-risk 
for significant TBI and has been largely overlooked. Their 
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preliminary results indicate that the degree of neuro-
trauma in women who sustain TBI through intimate 
partner violence is sufficient to produce changes in 
white matter integrity visible with 3T MRI neuroimaging. 
As the authors point out, the number of women that 
could be affected vastly overwhelms that of professional 
contact sport athletes or even those with non-
professional participation in such sporting activities. The 
underlying neuropathologic nature of damage related to 
this form of neurotrauma remains unstudied and is an 
issue that clearly needs further investigation. 
Advances in the Investigation of the 
Effects of Repeated Impact TBI on the 
Development of Neurodegeneration 
(Chronic Traumatic Encephalopathy, 
CTE) 
There has been considerable interest in the subse-
quent development of neurodegeneration following 
repeated impact TBI, particularly in the form of CTE. In 
specific, this has involved concerns about how prevalent 
the disorder is among professional contact sport ath-
letes and, more broadly, about possible risks to the gen-
eral public following much lesser extents of TBI expo-
sure. In 2019, these concerns have been addressed in a 
number of ways. 
Currently, CTE can only be diagnosed by neuro-
pathologic examination of the brain at autopsy. Clinical-
ly, there is a considerable need to identify an approach 
by which patients at-risk for this condition can be evalu-
ated and confidently diagnosed during life. For the most 
part, this effort has involved the use of a variety of posi-
tron emission tomography (PET)-scan ligands directed 
against tau deposits in the brains of at-risk subjects 
(Dickstein, Pullman et al. 2016, Marquie, Normandin et 
al. 2017). The use of similar PET ligands directed at beta-
amyloid has been employed with considerable success in 
the diagnostic work-up of patients thought to be suffer-
ing from Alzheimer’s disease and this paper (Stern, Adler 
et al. 2019) represents the use of similar approaches for 
CTE, a form of tauopathy. 
In a 2019 study (Stern, Adler et al. 2019), 26 former 
National Football League (NFL) players and 31 controls 
were evaluated using both flortaucipir and florbetapir 
PET ligands, reagents directed against tau and beta-
amyloid, respectively (Wong, Rosenberg et al. 2010, 
Marquie, Siao Tick Chong et al. 2017) . The former foot-
ball players had a minimum of 2 years playing in the NFL 
(mean 9.1 years ± 3.0) and a minimum of 12 years total 
football playing experience (mean 18.8 years ± 4.6). All 
participants reported to be suffering from cognitive, 
mood, and behavioral symptomatology. The controls 
were free of a history of TBI or evidence of cognitive 
impairment. The former football player cohort showed 
significantly elevated uptake by the tau PET ligand in the 
three neuroanatomic regions that had been examined 
(bilateral superior frontal, bilateral medial temporal and 
left parietal areas) when compared to that of the control 
group. There was no difference between groups in the 
beta-amyloid directed PET results. 
As the authors point out, the differences noted 
were based on collective group findings and the results 
“do not inform the use of testing in individual patients to 
determine CTE pathology during life.” At the time of 
publication, all of the participants in this study are pre-
sumably still alive and thus there was no opportunity to 
validate the findings with post-mortem assessment. This 
is an important first step but validation using a much 
large sample will be necessary to determine the specific-
ity and sensitivity of this approach to the diagnosis of at-
risk individual patients. Neuropathologists will need to 
be actively involved in such studies, particularly in at-
tempts to identify individuals with CTE and distinguish 
them from patients with other forms of neurodegenera-
tive disorders, especially other forms of tauopathies. 
Most studies to date have depicted CTE in patients 
who participated in boxing or American professional 
football. In 2019, an epidemiologic study appeared doc-
umenting evidence of an increased incidence of neuro-
degenerative disorders among individuals who had been 
former professional soccer players (Mackay, Russell et 
al. 2019). The authors used mortality data derived from 
the death certificates of 7,676 former Scottish profes-
sional soccer players and compared them to 23,028 
controls that were drawn from the general population. 
Further, they compared prescription information on the 
use of medications prescribed for the treatment of de-
mentia between the two groups. The results indicated 
that Scottish professional soccer players had a lower all-
cause mortality rate than the general population but 
showed a significantly increased tendency to die of all 
forms of neurodegenerative disease. Indeed, significant-
ly higher mortality rates from 1) dementia, not other-
wise specified, 2) Alzheimer’s disease, 3) non-
Alzheimer’s dementias, 4) motor neuron disease and 5) 
Parkinson’s disease were all seen in the former soccer 
players when compared to general population controls. 
Recognizing the weakness of possible errors in death 
certificates’ stated causes of death, the authors turned 
to the prescription data for drugs used to treat demen-
tia, showing a higher rate of use among the former soc-
cer players. 
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Obviously, there was no opportunity to verify by 
autopsy examination the indicated causes of death on 
the death certificates. However, errors in ascribing such 
deaths would be expected to be roughly equal among 
the athletes and the controls. This study expands the 
growing epidemiologic literature supporting the concept 
that repeated head trauma has a correlation with the 
subsequent development of neurodegenerative diseases 
and dementia. The nature of that association and, in 
particular, whether it speaks to the induction of CTE 
and/or Alzheimer’s disease, Parkinson’s disease or amy-
otrophic lateral sclerosis, will require additional study 
and neuropathologic investigation of incident cases. This 
paper points to the importance of such studies in the 
future. As an additional point, the authors remind their 
readers that soccer is played in over 200 countries 
worldwide with more than a quarter billion participants. 
While this study could not address the risks of more 
casual amateur play, it does raise further concerns re-
garding the long-term consequences of repeated head 
trauma, a subject that is likely to attract increasing in-
terest and research in the coming years. 
Attempts to Model Chronic Traumatic 
Encephalopathy (CTE) in Rodents 
Chronic traumatic encephalopathy (CTE) is a pro-
gressive neurodegenerative disease that has been close-
ly linked to repeated head trauma, primarily in the set-
ting of participation in contact sport athletics. The neu-
ropathologic features of CTE include deposition of ab-
normally phosphorylated tau in neurons and astrocytes 
in a unique and distinguishable pattern (McKee, Cairns 
et al. 2016) (see Figure 2). Despite considerable efforts, 
no laboratory has been able to produce a consistent and 
appropriate experimental model of CTE. In 2019, two 
papers (Gangolli, Benetatos et al. 2019, Mouzon, Bach-
meier et al. 2019) described efforts to do so using differ-
ing impact rodent models and both failed to induce 
intraneuronal tau deposits in their injured animals. 
First and foremost, one needs to recognize that 
rodent tau is different from human tau and there has  
 
 
 
Figure 2. Characteristic tau neuropathology features of chronic traumatic encephalopathy (CTE), including: A. depth of sulcus in-
volvement, B,C. perivascular foci with involvement of neurons and astrocytes, and D. neurofibrillary tangles in substantia nigra, pars 
compacta neurons (arrows). Hyperphosphorylated tau immunohistochemistry (AT-8) in a former collegiate American football player. 
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been an almost universal failure, under any experi-
mental condition, to induce tau aggregates comparable 
to human neurofibrillary tangles in wild-type mice. Ac-
cordingly, both groups used a humanized mouse trans-
genic model with knock out of the expression of the 
native mouse tau, in the hopes that this maneuver 
would enhance their chances of inducing such changes. 
In the Gangolli et al. (Gangolli, Benetatos et al. 
2019) experiment, head trauma was produce using the 
Closed-Head Impact Model of Engineered Rotational 
Acceleration (CHIMERA) approach. CHIMERA is a rela-
tively newly developed technology that is capable of 
producing both concussive and subconcussive injury to 
experimental animals and also produces a significant 
rotational acceleration component (Namjoshi, Cheng et 
al. 2017). Mice were exposed to 20 daily impacts for 20 
consecutive days and the energy used for the CHIMERA 
impact was controlled to yield animals with either a 
subconcussive or concussive level of injury. All animals 
underwent behavioral testing at 3 months and 12 
months post-injury and were sacrificed for morphologic 
and biochemical studies at the later time period.  Behav-
ioral abnormalities were seen in both the subconcussive 
and concussive-exposed animals (more prominent fol-
lowing the higher energy impact model) and this was 
accompanied by evidence of white matter disruption. 
Importantly, there was no evidence of tau pathology in 
any of the injured animals. Clearly, these experiments 
demonstrated that repeated exposure to head trauma 
through the CHIMERA approach could induce white 
matter damage, important in and of itself, but this failed 
to induce a model that could be used in studying the 
underlying tau-related pathophysiology of CTE. 
The Mouzon, et al. paper (Mouzon, Bachmeier et 
al. 2019) reports exposing humanized transgenic mice to 
closed-head impact injury with either a single blow or 5 
successive blows over a ten day interval (48 hours 
apart). The animals were then allowed to survive for 
either 24 hours or 12 months, post-injury. Evaluations 
included behavioral testing and, on sacrifice, morpholog-
ic and biochemical assays. The behavioral testing 
showed persistent and progressively worsening deficits 
in visuospatial learning from 2 to 12 months and signifi-
cant deficits in visuospatial memory consolidation at 12 
months post-injury. Neuropathologic evaluation at both 
24 hours and 12 months revealed evidence of axonal 
injury, thinning of the corpus callosum and activation of 
microglia and astrogliosis in the white matter. Tau im-
munohistochemistry and ELISA studies showed an in-
crease in phosphorylated tau in the cortex at the site 
below the impact point and in the CA1/CA3 region of the 
hippocampus of both the single and repeated injury 
mice. However, this response was transitory in the im-
mediate post-injury (24 hours) phase and was not de-
tected at the 12-month survival time period. No neu-
ronal tau aggregates were detected in the injured ani-
mals. The authors point out that the “post-TBI neuropa-
thology in hTau and WT mice was otherwise compara-
ble, with essentially similar levels of axonal injury and 
chronic neuroinflammation in both study groups.” They 
further suggested that the observation of transient tau 
hyperphosphorylation at acute time periods post-injury 
“may be a normal physiologic response of the brain to 
mTBI.” 
Both articles failed to show that the use of human-
ized tau mice with repeated impact TBI was able to de-
velop a rodent model of CTE and thus their results could 
not be used to mimic the human disease. In my opinion, 
despite considerable effort, the neurotrauma field has 
yet to identify a consistent and valid animal model of 
CTE. 
Characterization of Tau Filaments in 
Chronic Traumatic Encephalopathy 
Cases by Cryo-Electron Microscopy 
Cryo-electron microscopy is a technology that is 
capable of imaging the three-dimensional structure of 
complex biomolecules at the single digit Angstrom level 
of resolution. This newly developed approach is so pow-
erful, that its developers, Drs. Jacques Dubochet, Joa-
chim Frank and Richard Henderson, were honored with 
the 2017 Nobel Prize in Chemistry for their work. Tau 
filaments isolated from the brains of patients with Alz-
heimer’s disease (Fitzpatrick, Falcon et al. 2017) and 
Pick’s disease (Falcon, Zhang et al. 2018) have been 
reported using this technique and have been shown to 
form differing configurations. In 2019, Falcon, et al. 
(Falcon, Zivanov et al. 2019) reported a cryo-EM study of 
tau filaments isolated from three cases of CTE (a former 
American football player and two former boxers). The 
configuration of the filaments isolated from each of the 
CTE cases were identical and were distinctly different 
than that isolated from the Alzheimer’s disease and 
Pick’s disease brains. In the CTE-derived tau filaments, 
the β-helix region of the molecule displayed a distinct 
hydrophobic cavity that was not seen in tau filaments 
from Alzheimer’s or Pick’s disease specimens. This cavity 
contained an additional density whose identify has yet 
to be identified but was thought to be a non-
proteinaceous co-factor. These exciting findings serve to 
define CTE as representing a distinct and different neu-
rodegenerative process from Alzheimer’s disease. In 
addition, the identity and function of the associated co-
factor represents a potentially exciting therapeutic tar-
get for patients with CTE. 
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Conclusions 
In this review a number of studies are presented, 
some involving clinically relevant issues while others use 
preclinical models to investigate pathophysiologic 
mechanisms related to neurotrauma. The studies dis-
cussed here have relevance to neuropathologists with an 
interest in aspects of neurotrauma, whether they be 
involved in clinical diagnostic issues or preclinical mod-
els. Despite the clinical importance of neurotrauma and 
its acute and long-term consequences, there exist major 
knowledge gaps throughout the field that require fur-
ther investigation. I hope the studies discussed here will 
help to stimulate neuropathologists, especially those 
newly entering the field, to become active in this im-
portant and fertile area of investigation. 
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